Smith+Nephew Unveils Chronic Wound Care Innovations at EWMA 2026
Event summary
- Smith+Nephew launches ALLEVYN™COMPLETE CARE Dressing and RENASYS™ EDGE tNPWT at EWMA 2026, targeting chronic wound management.
- ALLEVYN™COMPLETE CARE features five-layer construction with ExuLOCK™ Technology, reducing bacterial release by up to 100x.
- RENASYS™ EDGE offers portable, low-maintenance negative pressure wound therapy with 88% patient compliance.
- EWMA Conference runs May 6-8, 2026, in Bremen, with Smith+Nephew at Booth E10.
The big picture
Smith+Nephew's launch of ALLEVYN™COMPLETE CARE and RENASYS™ EDGE underscores its strategic focus on chronic wound management, an area affecting 14.9 million people in Europe. The innovations align with broader industry trends toward patient-centric care and early intervention, positioning the company to capitalize on the growing demand for advanced wound care solutions. With annual sales of $6.2 billion in 2025, Smith+Nephew is well-positioned to drive progress in this critical healthcare segment.
What we're watching
- Market Penetration
- Whether Smith+Nephew can leverage these innovations to capture a larger share of the €4% healthcare spend on chronic wound care in Europe.
- Regulatory Dynamics
- How MedTech Europe's white paper on wound care will influence reimbursement and adoption of advanced wound management solutions.
- Competitive Response
- The pace at which competitors introduce similar technologies, particularly in negative pressure wound therapy and foam dressings.